SecBot SecBot
8-K ·Filed Aug 11, 2026

PDSB

PDS Biotechnology Corp
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001140361-26-032142
8-K context-dependent: Items 7.01
Actionable Insight ▼ Bearish

The discontinuation of the PDS0101 Phase 3 trial is a significant negative catalyst, effectively writing off the company's most advanced asset. The entire valuation now rests on PDS0301 Phase 2b data expected over the next 18-24 months, creating a binary, high-risk profile. Traders should monitor for any partnership announcements for PDS0101 and the upcoming Q2 earnings on August 13 for cash runway details.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

PDSB drug pipeline →

PDS0301

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
Next catalyst
None dated

What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.2570
T+0 close · Aug 11, 2026 · via day close
Latest settled
+394.16%
T+60 · $1.27
Vs SPY
+394.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $0.2570entry
  2. T+1 · 3mo ago −5.84%α −6.09% · $0.2420
  3. T+5 · 3mo ago −19.07%α −18.66% · $0.2080
  4. T+20 · 2mo ago +14.01%α +15.07% · $0.2930
  5. T+60 · 13d ago +394.16%α +394.30% · $1.27
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology announced a strategic refocus prioritizing PDS0301 in metastatic colorectal cancer (mCRC) and discontinuing internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, seeking a partnership for PDS0101 instead. The company cited encouraging Phase 2 data for PDS0301, including a 71% ORR at 6 months and 80% 24-month survival in MSS/pMMR mCRC with liver metastases. This is a material pipeline restructuring that abandons the most advanced program (PDS0101 Phase 3) in favor of an earlier-stage asset, creating significant binary risk around PDS0301's upcoming Phase 2b data.

Key Facts

  • PDS Biotech is discontinuing the PDS0101 Phase 3 VERSATILE-003 trial and ceasing further internal investment in PDS0101.
  • The company is prioritizing PDS0301, an earlier-stage tumor-targeted immunocytokine, as its lead development program.
  • PDS0301 Phase 2 data in MSS/pMMR mCRC with liver metastases showed a 71% ORR at 6 months and an 80% 24-month survival rate.
  • PDS0301 has been evaluated in over 380 patients with an encouraging safety profile.
  • A randomized Phase 2b trial for PDS0301 has been designed with FDA feedback, with advancement expected over the next 18-24 months.
  • The company will announce Q2 2026 financial results on August 13, 2026.

Financial Impact

No financial figures provided in the filing. The company is a clinical-stage biotech with no approved products or reported revenue. The strategic refocus involves discontinuing the most advanced pipeline program (PDS0101 Phase 3), which represents a significant write-off of prior development investment.

pipeline valueR&D expenditurecash runway

Risk Factors

  • PDS0301 Phase 2b trial may fail to replicate earlier efficacy signals, resulting in a complete loss of enterprise value.
  • No partnership for PDS0101 may materialize, leaving zero value from that program.
  • Cash runway may be insufficient to complete the PDS0301 Phase 2b trial without dilutive financing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-032142
Document: ef20079931_8k.htm0001140361-26-032142
Document: 0001140361-26-032142-index-headers.html0001140361-26-032142
Document: 0001140361-26-032142-index.html0001140361-26-032142
Document: 0001140361-26-032142.txt0001140361-26-032142

Track record

28 reports on PDSB

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026